Related Experiment Videos
[What's new in oncodermatology?]
1Chef du service de dermato-oncologie et INSERM U 981, Gustave-Roussy, université Paris-Sud, Le Kremlin-Bicêtre, France.
Abstract:
This year again, several breaking news were published in our field of oncodermatology, especially in the domain of immunotherapy. Many works have reported results on predictive biomarker identification. Concerning melanoma treatment, we were disappointed by the negative results of the phase III trial evaluating the IDO1 inhibitor epacadostat + pembrolizumab versus pembrolizumab. However, many promising preliminary results involving the combinations of anti-PD1 and innate immunity activators have been published. We also have a new anti-BRAF + anti-MEK combination: encorafenib + binimetinib with a good benefit/risk ratio and a particularly favorable safety profile as compared with existing similar combinations. Major steps forward were obtained for locally advanced Merkel cell carcinoma and squamous cell carcinoma with anti-PDL-1 avelumab and anti-PD1 cemiplimab respectively.
Insights
This year in oncodermatology, immunotherapy research yielded mixed results. While epacadostat failed in melanoma trials, new combinations show promise for various skin cancers.
Area of Science:
- Oncodermatology
- Immunotherapy
- Cancer Treatment
Background:
- Recent advancements in oncodermatology have focused on immunotherapy and predictive biomarkers.
- Immunotherapy, particularly targeting PD-1/PD-L1 pathways, has revolutionized cancer treatment.
- Predictive biomarkers are crucial for optimizing treatment selection and patient outcomes.
Purpose of the Study:
- To review significant developments in oncodermatology, focusing on immunotherapy advancements and treatment outcomes.
- To highlight new therapeutic combinations and their efficacy in various skin cancers.
- To discuss the impact of recent clinical trial results on current treatment paradigms.
Main Methods:
- Review of published literature and clinical trial results in oncodermatology.
- Analysis of data from phase III trials and preliminary studies on novel drug combinations.
- Evaluation of treatment efficacy, safety profiles, and biomarker research.
Main Results:
- The IDO1 inhibitor epacadostat combined with pembrolizumab showed negative results in a phase III melanoma trial.
- Promising preliminary results emerged from combinations of anti-PD1 therapies with innate immunity activators.
- Encorafenib plus binimetinib demonstrated a favorable benefit/risk and safety profile for melanoma treatment.
- Significant progress was observed in treating Merkel cell carcinoma and squamous cell carcinoma with anti-PD-L1 (avelumab) and anti-PD-1 (cemiplimab) therapies, respectively.
Conclusions:
- Immunotherapy continues to evolve in oncodermatology, with ongoing research into novel combinations and biomarkers.
- While some approaches like epacadostat have faced setbacks, new therapeutic strategies offer significant potential.
- Advances in targeted therapies and immune checkpoint inhibitors are improving outcomes for advanced skin cancers.